Kinnate Biopharma is a biotechnology business based in the US. Kinnate Biopharma shares (KNTE) are listed on the NASDAQ and all prices are listed in US Dollars. Kinnate Biopharma employs 84 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $1.04 - $2.69 |
| 50-day moving average | $2.49 |
| 200-day moving average | $2.24 |
| Wall St. target price | $2.36 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-04-15
| 1 week (2024-08-26) | nan% |
|---|---|
| 1 month (2024-08-02) | nan% |
| 3 months (2024-06-02) | nan% |
| 6 months (2024-03-06) | -100.00% |
| 1 year (2023-09-06) | -100.00% |
|---|---|
| 2 years (2022-09-06) | -100.00% |
| 3 years (2021-09-03) | 23.73 |
| 5 years (2019-09-02) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -33.63% |
| Return on equity TTM | -55.8% |
| Profit margin | 0% |
| Book value | $3.66 |
| Market Capitalization | $125 million |
TTM: trailing 12 months
We're not expecting Kinnate Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Kinnate Biopharma's shares have ranged in value from as little as $1.04 up to $2.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kinnate Biopharma's is 1.34. This would suggest that Kinnate Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Kinnate Biopharma's beta into context you can compare it against those of similar companies.
Kinnate Biopharma Inc. , a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. .
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Compare pros, cons, research tools and reviews for these two trading platforms.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.